Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice

References

• ManciaGFagardRNarkiewiczK2013ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)Eur Heart JJune142013 [Epub ahead of print.]
   Google Scholar
• ManciaGDe BackerGDominiczakA2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial HypertensionJ Hypertens20072591751176217762635
   PubMed Web of Science ®Google Scholar
• ManciaGLaurentSAgabiti-RoseiEReappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force documentJ Hypertens200927112121215819838131
   PubMed Web of Science ®Google Scholar
• SchmiederREHilgersKFSchlaichMPSchmidtBMRenin-angiotensin system and cardiovascular riskLancet200736995681208121917416265
   PubMed Web of Science ®Google Scholar
• BramlagePFixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertensionExpert Opin Pharmacother200910111755176719538001
   PubMed Web of Science ®Google Scholar
• ChrysantSGWeberMAWangACHinmanDJEvaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazideAm J Hypertens200417325225915001200
   PubMed Web of Science ®Google Scholar
• KereiakesDJNeutelJStoakesKAThe effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and olderJ Clin Hypertens (Greenwich)200911841142119695028
   PubMed Web of Science ®Google Scholar
• KereiakesDJNeutelJMSeated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitusDrugs R D201111325125721777013
   PubMedGoogle Scholar
• KereiakesDJNeutelJMPunziHAXuJLipkaLJDubielREfficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylateAm J Cardiovasc Drugs20077536137217953475
   PubMed Web of Science ®Google Scholar
• OparilSChrysantSGKereiakesDResults of an olmesartan medoxomil-based treatment regimen in hypertensive patientsJ Clin Hypertens (Greenwich)2008101291192119120717
   PubMed Web of Science ®Google Scholar
• RumpLCGirerdXSellinLStegbauerJEffects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertensionJ Hum Hypertens201125956557421107435
   PubMed Web of Science ®Google Scholar
• NarkiewiczKAngiotensin II receptor blocker combinations: from guidelines to clinical practiceBlood Press2012212738121830845
   PubMed Web of Science ®Google Scholar
• PescatelloLSFranklinBAFagardRAmerican College of Sports Medicine position stand. Exercise and hypertensionMed Sci Sports Exerc200436353355315076798
   PubMed Web of Science ®Google Scholar
• CornelissenVAFagardRHEffects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factorsHypertension200546466767516157788
   PubMed Web of Science ®Google Scholar
• JamesWPTSchofieldECHuman Energy Requirements A Manual for Planners and NutritionistsNew York, NYOxford University Press1990
   Google Scholar
• RuilopeLMClinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertensionVasc Health Risk Manag2008461237124819337537
   PubMedGoogle Scholar
• RumpLCSellinLCombination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazideExpert Opin Pharmacother201011132231224220707758
   PubMed Web of Science ®Google Scholar
• PunziHAIntegrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combinationIntegr Blood Press Control20114738322253546
   PubMedGoogle Scholar
• OparilSPimentaEEfficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sexJ Clin Hypertens (Greenwich)201012131320047622
   PubMed Web of Science ®Google Scholar
• GerminoFWNeutelJMDubielRMaaJFChavanuKJEfficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertensionAm J Cardiovasc Drugs201212532533322920048
   PubMed Web of Science ®Google Scholar
• BlacherJStaessenJAGirerdXPulse pressure not mean pressure determines cardiovascular risk in older hypertensive patientsArch Intern Med200016081085108910789600
   PubMed Web of Science ®Google Scholar
• LaurentSCockcroftJVan BortelLExpert consensus document on arterial stiffness: methodological issues and clinical applicationsEur Heart J200627212588260517000623
   PubMed Web of Science ®Google Scholar
• FogariRTaddeiSHolm-BentzenMBaszakJMelaniLSchumacherKEfficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III studyClin Drug Investig2010309581597
   PubMed Web of Science ®Google Scholar
• IzzoJLJrNeutelJMSilfaniTDubielRWalkerFTitration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blockerJ Clin Hypertens (Greenwich)200791454817215658
   PubMedGoogle Scholar
• NeutelJMKereiakesDJWaverczakWFStoakesKAXuJShojaeeAEffects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetesCurr Med Res Opin201026372172820085534
   PubMed Web of Science ®Google Scholar
• ScholzeJSchaeferAKreutzRSafety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patientsExpert Opin Drug Saf201110218519621254872
   PubMed Web of Science ®Google Scholar
• FossumEGleimGWKjeldsenSEThe effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE studyJ Intern Med2007262443944817875180
   PubMed Web of Science ®Google Scholar
• FagardRHThe role of exercise in blood pressure control: supportive evidenceJ Hypertens19951311122312278984117
   PubMed Web of Science ®Google Scholar
• Garcia-OrtizLGrandesGSanchez-PerezAEffect on cardiovascular risk of an intervention by family physicians to promote physical exercise among sedentary individualsRev Esp Cardiol201063111244125221070720
   PubMed Web of Science ®Google Scholar
• KetelhutRGFranzIWScholzeJRegular exercise as an effective approach in antihypertensive therapyMed Sci Sports Exerc20043614814707760
   PubMed Web of Science ®Google Scholar
• ChapmanJQureshiNKaiJEffectiveness of physical activity and dietary interventions in South Asian populations: a systematic reviewBr J Gen Pract201363607104114
   Web of Science ®Google Scholar